Back to Journals » Lung Cancer: Targets and Therapy » Volume 15 » default
Lung Cancer: Targets and Therapy
- View all (212)
- Volume 17, 2026 (4)
- Volume 16, 2025 (17)
- Volume 15, 2024 (19)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Archive: Volume 15, 2024
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
Lee AT, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:169-176
Published Date: 17 December 2024
Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
Luo FX, Arter ZL
Lung Cancer: Targets and Therapy 2024, 15:161-167
Published Date: 30 October 2024
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
Shim JS, Kim Y, Yuh T, Lee JB, Kim HR, Hong MH, Cho BC, Lim SM
Lung Cancer: Targets and Therapy 2024, 15:149-159
Published Date: 30 October 2024
NRG1 Fusions in NSCLC: Being eNRGy Conscious
Gupta B, Gosa Barrett L, Liu SV
Lung Cancer: Targets and Therapy 2024, 15:143-148
Published Date: 3 October 2024
Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the Literature
Liu Q, Zhang J, Wei M, Zhou X, Sun H, Dong Y, Zhang D
Lung Cancer: Targets and Therapy 2024, 15:135-142
Published Date: 29 August 2024
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:129-133
Published Date: 28 August 2024
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation
Zhu J, Chen J, Liu W, Zhang J, Gu Y
Lung Cancer: Targets and Therapy 2024, 15:123-128
Published Date: 27 August 2024
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:115-121
Published Date: 9 July 2024
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DW, Santos ES, Shum E, Lau SC, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, Tanizaki J, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, Soo RA
Lung Cancer: Targets and Therapy 2024, 15:87-114
Published Date: 22 June 2024
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?
Lee JB, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:81-85
Published Date: 25 May 2024
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:75-80
Published Date: 23 May 2024
“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)
Luo FX, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:69-73
Published Date: 18 May 2024
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer
González-Cao M, Cai X, Bracht JWP, Han X, Yang Y, Pedraz-Valdunciel C, Morán T, García-Corbacho J, Aguilar A, Bernabé R, De Marchi P, Sussuchi da Silva L, Leal LF, Reis RM, Codony-Servat J, Jantus-Lewintre E, Molina-Vila MA, Cao P, Rosell R
Lung Cancer: Targets and Therapy 2024, 15:55-67
Published Date: 9 May 2024
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
Kaakour D, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:49-54
Published Date: 23 April 2024
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:41-47
Published Date: 12 April 2024
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
Dou XJ, Ma RY, Ren DW, Liu Q, Yan P
Lung Cancer: Targets and Therapy 2024, 15:29-40
Published Date: 25 March 2024
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:19-27
Published Date: 27 February 2024
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu’s Approach
Wang B, Wang J, Sun T, Ding Y, Li S, Lu H
Lung Cancer: Targets and Therapy 2024, 15:9-17
Published Date: 2 February 2024
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:1-8
Published Date: 25 January 2024